Copyright
©The Author(s) 2023.
World J Clin Cases. Mar 26, 2023; 11(9): 1903-1917
Published online Mar 26, 2023. doi: 10.12998/wjcc.v11.i9.1903
Published online Mar 26, 2023. doi: 10.12998/wjcc.v11.i9.1903
Ref. | Sample | Age (yr) | % female | Diagnosis of depression | EEG detail | |||||
Experimental group | Control group | Experimental group | Control group | Reference montage | EO/EC | Recording length (min) | Alpha range (Hz) | |||
Henriques et al[20], 1991 | EG: 15 depressed subjects | CG: 13 healthy controls | M = 40.40 (depressed subjects) | M = 40.61 (HCs) | 60.7 | SADS | CZ; AE; AR | E0+EC | 1 | 8–13 |
Baehr et al[21], 1998 | EG: 13 MDD | CG: 11 healthy controls | M = 43.50 (MDD) | M = 44.20 (HCs) | DSM-IV; BDI | Cz | EC | 5 | 8–13 | |
Beeney et al[22], 2014 | EG: 13 MDD | CG: 21 healthy controls | M = 32.12 (MDD) | M = 27.78 (HCs) | 100 | DSM–IV; SCID | AL | E0+EC | 8 | 8–13 |
Bruder et al[23], 1997 | EG: 44 MDD (19 with and 25 without an anxiety disorder) | CG: 26 healthy controls | MDD with an anxiety disorder: M = 36.70; MDD without an anxiety disorder: M = 41.30 | M = 32.90 (HCs) | 50 | DSM-III-R | NR | E0+EC | 6 | 7.8–12.5 |
Cantisani et al[24], 2016 | EG: 20 depressed subjects | CG: 19 healthy controls | M = 43.30 (depressed subjects) | M = 41.05 (HCs) | 53.8 | SCID; DSM-IV-TR | CA | 6 | 8–12.5 | |
Dharmadhikari et al[25], 2019 | EG: 24 MDD | CG: 17 healthy controls | M = 34.82 (MDD) | M = 29.52 (HCs) | 63.4 | DSM-IV | auricle | EC | 10 | 8--13 |
Gordon et al[26], 2010 | EG: 92 MDD | CG: 1908 healthy controls | 58.7 | DSM-IV | AR | E0+EC | 4 | 8–13 | ||
Gotlib[27], 1998 | EG: 16 currently depressed, 31 previously depressed | CG: 30 never depressed | SCID | Cz | E0+EC | 8 | 8–13 | |||
Jaworska et al[28], 2012 | EG: 53 MDD | CG: 43 healthy controls | DSM-IV-TR; SCID-IV-I/P; HAMD; MADRS | AM; CZ; AR | E0+EC | 6 | 8–13 | |||
Kemp et al[29], 2010 | EG: 15 MDD | CG: 15 healthy controls | M = 39.90 (MDD) | M = 42.40 (HCs) | 60 | MINI; DASS | AM | EC | 2 | 8–13 |
Koo et al[30], 2019 | EG: 20 MDD | CG: 20 healthy controls | M = 51.05 (MDD) | M = 47.15 (HCs) | ICD-10/DSM IV | AE | EC | 10 | 8–13 | |
Roh et al[31], 2020 | EG: 44 MDD without Suicidal ideation, 23 MDD with suicidal ideation | CG: 60 healthy controls | M = 39.30 (MDD); M = 37.48 (MDD with SI) | M = 34.83 (HCs) | 85 | DSM-IV | ECC | EO | 3 | 8–12 |
Stewart et al[32], 2010 | EG: 143 MDD | CG: 163 healthy controls | M = 19.10 (MDD) | 69 | DSM-IV | CSD; Cz; LM | E0+EC | 8 | 8–13 | |
Cai et al[34], 2020 | EG: 24 MDD | CG: 22 healthy controls | DSM-IV; MINI | Cz | EC | 5 | 8–14 | |||
Nusslock et al[35], 2018 | EG: 37 depression, 18 anxiety + depression | CG: 69 healthy controls | SCID | AM | E0+EC | 6 | 8–13 | |||
Brzezicka et al[36], 2017 | EG: 26 MDD | CG: 26 healthy controls | M = 28.00 (MDD) | M = 24.90 (HCs) | CSD | EC | 5 | 8–13 | ||
Jang et al[37], 2020 | EG: 20 MDD, 18 patients with schizophrenia | CG: 16 healthy controls | M = 42.60 (MDD); M = 32.00 (MDD with schizophrenia) | M = 37.75 (HCs) | 48.1 | DSM-IV; MINI | BM | E0+EC | 5 | 8–12 |
Segrave et al[38], 2011 | EG: 16 MDD | CG: 18 healthy controls | M = 40.75 (MDD) | M = 42.11 (HCs) | 100 | DSM-IV | Cz; CA | E0+EC | 6 | 8–13 |
Quinn et al[39], 2014 | EG: 117 MDD | CG: 120 healthy controls | MINI; DSM-IV | AR; ER | EC | 2 | 8–13 | |||
Smith et al[99], 2018 | EG:143 lifetime MDD, 62 current MDD | CG: 163 healthy control | 69 | BDI; SCID | Cz | E0+EC | 8 | 8–13 | ||
Vuga et al[40], 2006 | EG: 49 childhood onset MDD | CG: 50 healthy controls | 19-34 | 19-39 | 66.7 | DSM-IV | Cz | E0+EC | 6 | 7.5–12.5; alpha 1 (7.5–10.5); alpha 2 (10.5–12.5) |
Gold et al[41], 2013 | EG: 79 adults with depression | M= 35.60 | 78.5 | DSM-III-R; SCID; MADRS | ALM | EC | 5 | 8–12 | ||
McFarland et al[42], 2006 | EG: 67 MDD | M = 34.64 | 65.7 | SCID | LE | E0+EC | 6 | 8–13 | ||
Kentgen et al[44], 2000 | EG: 25 right-handed female outpatients | CG: 10 healthy controls | 100 | DSM-IV | NR | E0+EC | 6 | 7.8--12.5 | ||
Feldmann et al[45], 2018 | EG: 16 adolescents with depression | CG: 34 healthy controls | M = 16.08 | M = 15.67 | 72.6 | ICD-10; BDI | Cz; Mastoids; AE | E0+EC | 8 | 7.5–13 |
Grünewald et al[46], 2018 | EG: 20 adolescents (12–17 yr) with unipolar depression (12 with fifirst episode, 8 with recurrent depression) | CG: 31 healthy controls | M = 14.85 (unipolar depression) | M = 14.16 (HCs) | 60.8 | DSM-IV; ICD-10 | AR | 5 | 7.5–13.5 | |
Deslandes et al[89], 2008 | EG: 22 depressed subjects | CG: 14 healthy controls | M = 71.60 (depressed subjects) | M = 72.40 (HCs) | 94 | DSM-IV | ER | E0+EC | 8 | 8–13 |
Kaiser et al[50], 2018 | EG: 14 depression, 11 anxiety + depression | CG: 14 healthy controls | M = 78.60 (anxiety + depression); m = 80.50 (depression) | M = 80.90 (HCs) | 100 | GDS; HADS | RLMB | E0+EC | 4 | 6.9–12.9 |
Carvalho et al[51], 2011 | EG: 12 depressed subjects, 8 remitted subjects | CG: 7 non-depresse elderly subjects | 66.7 | DSM-IV | Earlobes | EC | 8 | 8–12.9 |
Ref. | Sample | Age (yr) | % female | Diagnosis of depression | EEG detail | |||||
Experimental group | Control group | Experimentalgroup | Control group | Reference montage | EO/EC | Recording length (min) | Alpha range (Hz) | |||
Dawson et al[54], 1997 | EG: 117 mothers and their 13-15-mo-old infants | 13.74 | 44.4 | DSM-IIIR; SCID; CES-D | ME | 1 | 6–9 | |||
Diego et al[56], 2006 | EG: 38 depressed | CG: 28 non-depressed | 3-6 mo | CES-D | Cz | 3–13 | ||||
Field et al[57], 1995 | EG: 17 depressed adolescent mothers | CG: 15 non-depressed mothers | 3-6 mo | 50 | DISC; BDI | Cz | 3 | 3–12 | ||
Jones et al[58], 1997 | EG: 20 depressed group | CG: 24 non-depressed group | M = 18.00 | M = 18.70 | CES-D; SCID | Cz | 3 | 2–6 | ||
Jones et al[59], 1998 | EG: 35 mothers with depressive symptom | CG: 28 non-depressive symptom | M = 38.80 | M = 39.50 | 48 | CES-D | Cz | 3 | 8.5–125 | |
Tomarken et al[60], 2004 | EG: 23 high risk | CG: 13 low risk | M = 13.10 | M = 13.00 | 52.6 | SCID | Cz | E0+EC | 8 | 8.5–12.5 |
Lopez-Duran et al[61], 2012 | EG: 90 high risk | CG: 45 low risk | M = 7.36 | M = 7.93 | 46.6 | DSM-IV; SCID | CA | E0+EC | 3 | 7.5–11.5 |
Goodman et al[63], 2020 | EG: 136 total infants. | M = 12 mo | DSM-IV | ARC | 3 | 6–9 | ||||
Wen et al[64], 2017 | EG: 111 infants | 6 mo of age (± 2 wk) | EPDS | Cz | 2 | 6–9 | ||||
Lusby et al[65], 2014 | EG: 83 mother–infant dyads participated | 3 mo and 6 mo only | DSM-IV | ARC | 3 | 6–9 | ||||
Dawson et al[69], 1992 | EG: 31 infants | M = 14.21 (mo) | 59.1 | CES-D | Cz | 1 | 6–9 | |||
Bruder et al[68], 2007 | EG: 19 both parent and grandparent having MDD; 14 either parent or grandparent having MDD | CG: 16 neither having MDD | M = 15.40; M = 10.60 | M = 13.60 | 53 | LE | E0+EC | 2 | 7–12.5 |
Ref. | Sample | Age (yr) | Intervention time | % female | Diagnosis of depression | EEG detail | |||||
Experimental group | Control group | Experimental group | Control group | Reference montage | EO/EC | Recording length (min) | Alpha range (Hz) | ||||
Arns et al[70], 2016 | EG: 236 Escitalopram, 251 Sertraline, 235 Venlafaxine-XR | CG: 336 controls | M = 38.85 (Escitalopram), M = 38.34 (Sertraline), M = 38.46 (Venlafaxine-XR), M = 37.84 (MDD) | M = 36.99 (Controls) | 8 wk | 57.03 | DSM–IV; MINI; HRSD | AM | E0+EC | 2 | 8–13 |
Vinne et al[71], 2019 | EG: 136 treatment with escitalo pram, 169 treatment with sertraline, 188 treatment with venlafaxine-extended release | 8 wk | 54.47 | MINI; HRSD; VQIDS-SR | AM | E0+EC | 4 | 8–13 | |||
Bares et al[72], 2019 | EG: 57 SSRIs, 46 SNRIs | M = 46.04 (SSRIs), M = 44.83 (SNRIs) | 1 wk | 74.76 | DSM IV; MADRS; CGI | Cz | EC | 10 | 8–13 | ||
Szumska et al[73], 2021 | EG: 12 Mindfulness group | CG: 8 control group | M = 32.40 (Mindfulness group) | M = 35.00 (Control group) | 8 wk | 55 | CES-D; MINI | Cz | E0+EC | 3 | 8–13 |
Keune et al[74], 2011 | EG: 78 MDD; 40 MBCT group | CG: 37 a wait-list condition | M = 48.93 (MBCT group) | M = 45.24 (wait-list group) | 8 wk | 74.03 | DSM-IV | AM | E0+EC | 8 | 8--13 |
Barnhofer et al[75], 2007 | EG: 10 MBCT | CG: 12 treatment-as-usual | M = 48.00 (MBCT) | M = 38.60 (treatment-as-usual) | 8 wk | 50 | MINI | AE | E0+EC | 8 | 8–13 |
Gollan et al[77], 2014 | EG: 37 MDD; Behavioral activation | CG: 35 non-MDD | 16 wk | 62.50 | DSM-IV; IDS-C | AM | E0+EC | 8 | 8–13 | ||
Allen et al[14], 2004 | EG: 30 nonpharmacological intervention | 8 wk | 100 | DSM–IV; HRSD | Cz; AM, AR | E0+EC | 8 | 8–13 | |||
Spronk et al[78], 2008 | EG: 8 MDD; rTMS Treatment | M = 42.60 (rTMS Treatment) | 37.50 | BDI; SCI | AM | E0+EC | 2 | alpha 1 (8–11); alpha 2 (11–13) | |||
Wang et al[80], 2016 | EG: 7 neurofeedback group | M = 47.43 | 6 wk | 78.57 | DSM-IV | Cz | EC | 5 | 8–12 | ||
Vlcek et al[79], 2020 | EG: 9 LF rTMS responder | CG: 16 LF rTMS non-responders | 4 wk | 80 | MINI; MADRS; CGI | Cz | EC | 10 | 8–12; 8–10; 10–12 |
- Citation: Xie YH, Zhang YM, Fan FF, Song XY, Liu L. Functional role of frontal electroencephalogram alpha asymmetry in the resting state in patients with depression: A review. World J Clin Cases 2023; 11(9): 1903-1917
- URL: https://www.wjgnet.com/2307-8960/full/v11/i9/1903.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v11.i9.1903